Bernd Kastler
Chief Executive Officer at Kastler GmbH
Profile
Bernd Kastler is currently the Managing Director at Kastler GmbH since 2015.
Previously, he worked as the Chief Executive Officer at elbion AG.
He also served as an Independent Director at Biotie Therapies Oy from 2008 to 2015.
Dr. Kastler obtained his doctorate degree from the University of Giessen in 1980.
Bernd Kastler active positions
| Companies | Position | Start |
|---|---|---|
Kastler GmbH
 Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Chief Executive Officer | - |
Former positions of Bernd Kastler
| Companies | Position | End |
|---|---|---|
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | President | - |
| BIOTIE THERAPIES CORP | Director/Board Member | - |
Training of Bernd Kastler
| University of Giessen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
elbion AG
elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
Kastler GmbH
Kastler GmbH Financial ConglomeratesFinance Kastler GmbH is an investment holding German company. The CEO of the private company is Bernd Kastler. | Finance |
- Stock Market
- Insiders
- Bernd Kastler
